This suggests that they could have a notable impact on the treatment of MDS, but also extends to a broader spectrum of clinical implications in other cancer types associated with the SF3B1 K700E mutation, underscoring the significance and widespread applicability of our findings. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.